Kempf, Amy

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 897

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 889

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Arora, P., Sidarovich, A., Moldenhauer, A.-S., Winkler, M. S., et al. (2021) · Cell Reports

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 258

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation

Hoffmann, M., Behrens, G. M. N., Arora, P., Kempf, A., Nehlmeier, I., Cossmann, A., Manthey, L., Dopfer-Jablonka, A., & Pöhlmann, S. (2023) · The Lancet Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 66

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., & Pöhlmann, S. (2021) · The Lancet

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 27